OneSource Specialty Pharma Limited delivered a robust Q4FY26 performance, with revenue climbing 47% QoQ to ₹4,282 million. Growth was fueled by the successful launch of semaglutide products in India and increased momentum across injectables and soft-gelatin business segments. The company reported an EBITDA of ₹919 million, expanding more than 5x over the previous quarter, and has reaffirmed its FY28 guidance of $400 million in organic revenue with ~40% EBITDA margin.
Quarterly Financial Highlights
OneSource Specialty Pharma reported a strong finish to the fiscal year, with Q4FY26 revenue of ₹4,282 million, a 47% increase compared to Q3FY26. Operating profitability saw significant improvement, with EBITDA reaching ₹919 million, reflecting an expansion of 1,550 bps in margin sequentially. The company also achieved a transition to profitability in the quarter, reporting an Adjusted PAT of ₹390 million with an Adjusted EPS of ₹3.4.
Strategic Growth Drivers
The performance was primarily driven by the company’s leadership in GLP-1 molecules, notably achieving the first generic semaglutide approvals in Canada and successful ‘Day-1’ commercial launches in India. The business saw strong traction in its injectables and softgels division, which recorded 10+ new contract and licensing deals alongside 15+ commercial launches during the year. Furthermore, the biologics pipeline is at an all-time high, supported by 4x growth in the biologics customer funnel.
Operational Outlook and Reaffirmed Guidance
Looking ahead, OneSource remains committed to its long-term growth strategy. The company has reaffirmed its FY28 target of $400 million in organic revenue and a ~40% steady-state EBITDA margin. Management noted that the expansion of the flagship manufacturing site is progressing, with ~$80 million already committed toward the total $100 million capex plan. Additionally, the company has announced that the proposed acquisition of specialty injectable assets has been paused, with plans to re-engage following the successful delivery of FY28 guidance.
Commitment to Excellence
Operational quality remains a core pillar for OneSource, evidenced by 49 successful regulatory inspections and customer audits in FY26 with zero critical observations. The company continues to hold a 100% GMP inspection success rate and has received key approvals from global regulatory bodies, including ANVISA and USFDA, positioning it to scale further in international markets throughout FY27.
Source: BSE
